|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis显示文摘Hepatitis C virus(HCV)is one of the main causes of liver disease worldwide,and alterations of glucose metabolism have reached pandemic proportions in western countries.However,the frequent coexistence between these two conditions is more than simply coincidental,since HCV can induce insulin resistance through several mechanisms.Indeed,the virus interferes with insulin signaling both directly and indirectly,inducing the production of pro-inflammatory cytokines.Furthermore,the entire viral life cycle has strict interconnections with lipid metabolism,and HCV is responsible for a'viral'steatosis which is frequently superimposed to a'metabolic'one.Several evidences suggest that HCV-induced metabolic disorders contribute both to the evolution of liver fibrosis and,likely,to the progression of the other disorders which are typically associated with altered metabolism,in particular atherosclerosis.In the present review,we will examine in depth the links between HCV infection and insulin resistance,liver steatosis and diabetes,and analyze the impact of these interactions on the progression of liver fibrosis and atherosclerosis.Special attention will be focused on the highly debated topic of the relationship between HCV infection and cardiovascular disease.The available clinical literature on this item will be broadly reviewed and all the mechanisms possibly implied will be discussed. | Umberto Vespasiani-Gentilucci Paolo Gallo Antonio De Vincentis Giovanni Galati Antonio Picardi | 2014 | World Journal of Gastroenterology2014，20，11： | 5 |
| 2 | Thrombocytopenia in chronic liver disease:Physiopathology and new therapeutic strategies before invasive procedures显示文摘Chronic liver disease is characterized by several hematological derangements resulting in a complex and barely rebalanced haemostatic environment.Thrombocytopenia is the most common abnormality observed in these patients and recent advances have led to researchers focus the attention on the multifactorial origin of thrombocytopenia and on the key role of thrombopoietin(TPO)in its physiopathology.Severe thrombocytopenia(platelet count<50000/μL)complicates the management of patients with chronic liver disease by increasing the potential risk of bleeding for invasive procedures,which may be therefore delayed or canceled even if lifesaving.In the very last years,the development of new drugs which exceed the limits of the current standard of care(platelet transfusions,either immediately before or during the procedure)paves the way to a new scenario in the management of this population of patients.Novel agents,such as the TPOreceptor agonists avatrombopag and lusutrombopag,have been developed in order to increase platelet production as an alternative to platelet transfusions.These agents have demonstrated a good profile in terms of efficacy and safety and will hopefully allow reducing limitations and risks associated with platelet transfusion,without any delay in scheduled interventions.Altogether,it is expected that patients with chronic liver disease will be able to face invasive procedures with one more string in their bow. | Paolo Gallo Francesca Terracciani Giulia Di Pasquale Matteo Esposito Antonio Picardi Umberto Vespasiani-Gentilucci | 2022 | World Journal of Gastroenterology2022，28，30： | 5 |
| 3 | 脾对比增强复合谐波超声检查对于提高霍奇金淋巴瘤病人的分期准确性:前瞻性研究显示文摘目的前瞻性比较对比增强复合谐波超声(US)、CT、18-氟脱氧葡萄糖正电子发射断层显像(FDG—PET)对初诊霍奇金淋巴瘤病人脾结节样浸润的检出效果。方法经机构审查委员会批准,病人知情同意后,在对连续100例霍奇金淋巴瘤病人进行治疗前分期,探查脾是否受累时,前瞻性比较复合谐波超声(33例病人静脉注射微泡对比剂)与CT、FDG—PET的检查结果。以上影像学手段发现恶性结节的提示征象时认为是淋巴瘤浸润;对于存在争议的病灶, | M. Picardi A. Soricelli F. Pane P. Zeppa E. Nicolai M. De Laurentiis 李瑞利(译) 沈文(校) | 2009 | 国际医学放射学杂志2009，32，4： | 5 |
| 4 | Fetal programming and early identification of newborns at high risk of free radical-mediated diseases显示文摘Nowadays metabolic syndrome represents a real outbreak affecting society. Paradoxically, pediatricians must feel involved in fighting this condition because of the latest evidences of developmental origins of adult diseases. Fetal programming occurs when the normal fetal development is disrupted by an abnormal insult applied to a critical point in intrauterine life. Placenta assumes a pivotal role in programming the fetal experience in utero due to the adaptive changes in structure and function. Pregnancy complications such as diabetes, intrauterine growth restriction, preeclampsia, and hypoxia are associated with placental dysfunction and programming. Many experimental studies have been conducted to explain the phenotypic consequences of fetal-placental perturbations that predispose to the genesis of metabolic syndrome, obesity, diabetes, hyperinsulinemia, hypertension, and cardiovascular disease in adulthood. In recent years, elucidating the mechanisms involved in such kind of process has become the challenge of scientific research. Oxidative stress may be the general underlying mechanism that links altered placental function to fetal programming. Maternal diabetes, prenatal hypoxic/ischaemic events, inflammatory/infective insults are specific triggers for an acute increase in free radicals generation. Early identification of fetuses and newborns at high risk of oxidative damage may be crucial to decrease infant and adult morbidity. | Serafina Perrone Antonino Santacroce Anna Picardi Giuseppe Buonocore | 2016 | World Journal of Clinical Pediatrics2016，5，2： | 4 |
| 5 | Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma显示文摘AIM:To evaluate if indolent B cell-non Hodgkin's lymphoma(B-NHL) and diffuse large B-cell lymphoma(DLBCL) in hepatitis C virus(HCV) positive patients could have different biological and clinical characteristics requiring different management strategies.METHODS:A group of 24 HCV related B-NHL patients(11 indolent,13 DLBCL) in whom the biological and clinical characteristics were described and confronted.Patients with DLBCL were managed with the standard of care of treatment.Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed.The outcomes of the different approaches were compared.RESULTS:Patients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype.Five of the 9 patients with indolent HCV-relatedB-NHL treated with only antiviral therapy,achieved a complete response of their onco-haematological disease(55%).Seven of the 13 DLBCL patients treated with immunochemotheraphy obtained a complete response(54%).CONCLUSION:HCV genotypes and duration of HCV infection differed between B-NHL subtypes.Indolent lymphomas can be managed with antiviral treatment,while DLBCL is not affected by the HCV infection. | Adriano M Pellicelli Massimo Marignani Valerio Zoli Mario Romano Aldo Morrone Lorenzo Nosotti Giuseppe Barbaro Antonio Picardi Umberto Vespasiani Gentilucci Daniele Remotti Cecilia D'Ambrosio Caterina Furlan Fabrizio Mecenate Ettore Mazzoni Ignazio Majolino Roberto Villani Arnaldo Andreoli Giorgio Barbarini | 2011 | World Journal of Hepatology2011，3，11： | 4 |
| 6 | Hepatitis C treatment in the elderly:New possibilities and controversies towards interferon-free regimens显示文摘Due to the progressive aging of the hepatitis C virus(HCV) population which have acquired the infection during its maximum spread after the Second World War, the management of the elderly HCV-infected patient is emerging as a hot topic. Unfortunately, although it is recognized that the progression of HCV-related liver disease gets faster with aging, and that even extrahepatic manifestations of HCV infection are probably worse in the elderly, till now, treatment attempts in this population have been significantly limited by the wellknown contraindications and side effects of interferon(IFN). The arrival of several new anti-HCV drugs, and the possibility to combine them in safe and effective anti-viral regimens, is relighting the hope of a cure for many elderly patients who had been cut out of IFN-based treatments. However, although these new regimens will be certainly more manageable, it should be underscored that IFN-free doesn't mean free from any contraindication or side-effect. Moreover, one issue which promises to become central is that of the possible interactions between antiviral therapy and the multiple drugs frequently assumed by elderly patients because of comorbidities. In this review, we will revise the epidemiology pointing to HCV as an infection of the elderly, the evidences that HCV harms the health of the aged patient more than that of the young one, and the available experiences of HCV treatment in the elderly with the 'old' IFN-based regimens and with the newer drugs. We will conclude that the availability of IFNfree regimens should prompt us to change our mind and consider a significantly larger number of possible candidates among elderly patients, who would take significant advantage from viral eradication. Rather than the anagraphic age, drug-drug interactions and, mainly in case of economic restrictions, an evaluation of life expectancy dependent on liver disease with respect to that dependent on comorbidities, are likely to be the key issues guiding treatment indication in the next future. The sooner we will change our mind with respect to an a priori obstacle for anti-HCV treatment in the elderly, the sooner we will begin to spare many aged HCV patients from avoidable liver-related complications. | Umberto Vespasiani-Gentilucci Giovanni Galati Paolo Gallo Antonio De Vincentis Elisabetta Riva Antonio Picardi | 2015 | World Journal of Gastroenterology2015，21，24： | 4 |
| 7 | Exhaled breath analysis in hepatology: State-of-the-art and perspectives显示文摘Liver disease is characterized by breath exhalation of peculiar volatile organic compounds(VOCs).Thanks to the availability of sensitive technologies for breath analysis,this empiric approach has recently gained increasing attention in the context of hepatology,following the good results obtained in other fields of medicine.After the first studies that led to the identification of selected VOCs for pathophysiological purposes,subsequent research has progressively turned towards the comprehensive assessment of exhaled breath for potential clinical application.Specific VOC patterns were found to discriminate subjects with liver cirrhosis,to rate disease severity,and,eventually,to forecast adverse clinical outcomes even beyond existing scores.Preliminary results suggest that breath analysis could be useful also for detecting and staging hepatic encephalopathy and for predicting steatohepatitis in patients with nonalcoholic fatty liver disease.However,clinical translation is still hampered by a number of methodological limitations,including the lack of standardization and the consequent poor comparability between studies and the absence of external validation of obtained results.Given the low-cost and easy execution at bedside of the new technologies(e-nose),larger and well-structured studies are expected in order to provide the adequate level of evidence to support VOC analysis in clinical practice. | Antonio De Vincentis Umberto Vespasiani-Gentilucci Anna Sabatini Raffaele Antonelli-Incalzi Antonio Picardi | 2019 | World Journal of Gastroenterology2019，25，30： | 3 |
| 8 | Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy显示文摘B cells lymphoma is one of the most challenging extrahepatic manifestations of hepatitis C virus(HCV). Recently, a new kind of B-cell lymphoma, named doublehit B(DHL), was characterized with an aggressive clinical course whereas a potential association with HCV was not investigated. The new antiviral direct agents(DAAs) against HCV are effective and curative in the majority of HCV infections. We report the first case, to our knowledge, of DHL and HCV-infection successfully treated by new DAAs. According to our experience, a DHL must be suspected in case of HCV-related lymphoma, and an early diagnosis could direct towards a different hematological management because a worse prognosis might be expected. A possible effect of DAAs on DHL regression should be investigated, but eradicating HCV would avoid life-threatening reactivation of viral hepatitis during pharmacological immunosuppression in oncohaematological diseases. | Giovanni Galati Lorenzo Rampa Umberto Vespasiani-Gentilucci Mirella Marino Francesco Pisani Carlo Cota Alessandro Guidi Antonio Picardi | 2016 | World Journal of Hepatology2016，8，29： | 2 |
| 9 | Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge显示文摘Non-cirrhotic portal hypertension is a poorly understood condition characterized by portal hypertension in the absence of conventional hepatic cirrhosis and described in association with blood coagulation disorders, myeloproliferative and immunological diseases and with exposure to toxic drugs. Very recently, precise classification criteria have been proposed in order to define four distinct subcategories. The present case highlights how the clinical presentation, the confounding results from imaging studies, and the difficulties in the histological evaluation often render cases of non-cirrhotic portal hypertension a real diagnostic challenge. It also underscores the classification problems which can be faced once this diagnosis is performed. Indeed, the different subcategories proposed result from the prevalent subtypes in a spectrum of hepatic regenerative responses to a variety of injuries determining microcirculatory dis-turbances. More flexibility in classification should derive from this etiopathogenic background. | Umberto Vespasiani Gentilucci Paolo Gallo Giuseppe Perrone Riccardo Del Vescovo Giovanni Galati Sandro Spataro Chiara Mazzarelli Adriano Pellicelli Antonella Afeltra Antonio Picardi | 2011 | World Journal of Gastroenterology2011，17，20： | 2 |
| 10 | Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables显示文摘Non-alcoholic fatty liver disease(NAFLD) has a prevalence of approximately 30% in western countries, and is emerging as the first cause of liver cirrhosis and hepatocellular carcinoma(HCC). Therefore, risk stratification emerges as fundamental in order to optimize human and economic resources, and genetics displays intrinsic characteristics suitable to fulfill this task. According to the available data, heritability estimates for hepatic fat content range from 20% to 70%, and an almost 80% of shared heritability has been found between hepatic fat content and fibrosis. The rs738409 single nucleotide polymorphism(SNP) in patatin-like phospholipase domain-containing protein 3 gene and the rs58542926 SNP in transmembrane 6 superfamily member 2 gene have been robustly associated with NAFLD and with its progression, but promising results have been obtained with many other SNPs. Moreover, there has been proof of the additive role of the different SNPs in determining liver damage, and there have been preliminary experiences in which risk scores created through a few genetic variants, alone or in combination with clinical variables, were associated with a strongly potentiated risk of NAFLD, non-alcoholic steatohepatitis(NASH), NASH fibrosis or NAFLD-HCC. However, to date, clinical translation of genetics in the field of NAFLD has been poor or absent. Fortunately, the research we have done seems to have placed us on the right path: We should rely on longitudinal rather than on cross-sectional studies; we should focus on relevant outcomes rather than on simple liver fat accumulation; and we should put together the genetic and clinical information. The hope is that combined genetic/clinical scores, derived from longitudinal studies and built on a few strong genetic variants and relevant clinical variables, will reach a significant predictive power, such as to have clinical utility for risk stratification at the single patient level and even to esteem the impact of intervention on the risk of disease-related outcomes. Well-structured future studies would demonstrate if this vision can become a reality. | Umberto Vespasiani-Gentilucci Paolo Gallo Chiara Dell' Unto Mara Volpentesta Raffaele Antonelli-Incalzi Antonio Picardi | 2018 | World Journal of Gastroenterology2018，24，43： | 2 |
| 11 | Liver focal lesions and hepatocellular carcinoma in cirrhotic patients: from screening to diagnosis显示文摘 | Zardi EM Uwechie V Picardi A | 2001 | Clin Ther2001，152，3： | 1 |
| 12 | Factors associated with generic and disease-specific quality of life in temporal lobe epilepsy显示文摘 | Meldolesi GN Picardi A Quarato PP | 2006 | Epilepsy Res2006，69，2： | 1 |
| 13 | Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon 显示文摘 | Hawa MI Picardi A Costanza F | 2006 | Clin Immunol2006，118，23： | 1 |
| 14 | Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal Cancer显示文摘 | Cilla S Caravatta L Picardi V | | 0，，04： | 1 |
| 15 | Platelet gel for treatment of mucocutaneous lesions related to graft- versus- host dis- ease after allogeneic humatopoietic stem cell transplant 显示文摘 | Picardi A Lanti A Cudillo L | 2010 | Transfusion2010，50，2： | 1 |
| 16 | Symptomstructure of acute mania:A factor study of the 24-item Brief Psy-chiatric Rating Scale in a national sample of patients hospitalizedfor a manic episode显示文摘 | Angelo Picardi Francesca Battisti Giovannide Girolamo | 2008 | Journal of Affective Disorders2008，108，12： | 1 |
| 17 | Diagnosis of acute foetal distress does not preclude banking of umbilical cord blood units显示文摘 | Picardi A Tamburini A Caravita T | | 0，，5： | 1 |
| 18 | Diabetes in chronic liver disease:from old concepts to new evidence 显示文摘 | Picardi A D'Avola D Gentilucci U V | 2006 | Diabetes Metab Res Rev2006，22，4： | 1 |
| 19 | Reduction of hyperhydricity in sunflower tissue culture显示文摘 | MAYOR L M NESTARES G ZORZOLI R PICARDI A | 2003 | Plant Cell Tissue and Organ Culture2003，72，： | 1 |
| 20 | Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer显示文摘 | Cilla S Caravatta L Picardi V | 2012 | Clin Oncol2012，24，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员